Showing results (41-50 of 55) with videos related to
Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2020
International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAActSheela Rao, Francesco Sclafani, Cathy Eng, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal CancerTimothy J Iveson, Alberto F Sobrero, Takayuki Yoshino, et al.Nucleic Acids Research|October 1, 2024
Ribosome Quality Control mitigates the cytotoxicity of ribosome collisions induced by 5-FluorouracilSusanta Chatterjee, Parisa Naeli, Okan Onar, et al.Journal of the National Cancer Institute|January 17, 2019
Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal CancerVictoria Gray, Sarah Briggs, Claire Palles, et al.The Lancet. Oncology|February 1, 2024
Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysisAnja L Frei, Anthony McGuigan, Ritik R A K Sinha, et al.Nature Communications|November 9, 2018
Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancerGordon C Jayson, Cong Zhou, Alison Backen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumorsSaifee A Mullamitha, Nhuan C Ton, Geoff J M Parker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority TrialTimothy Iveson, Mark P Saunders, Caroline Kelly, et al.JAMA Surgery|June 12, 2024
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical TrialMikail Gögenur, Andreas Weinberger Rosen, Timothy Iveson, et al.The Journal of Clinical Investigation|November 7, 2023
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammationMagnus T Dillon, Jeane Guevara, Kabir Mohammed, et al.Pageof 6